Document is current
Any future updates will be listed below
-
Authors
Schwartz, Andrew J.
Goyert, Joshua W. https://orcid.org/0000-0003-3820-970X
Solanki, Sumeet
Kerk, Samuel A. https://orcid.org/0000-0001-9786-2245
Chen, Brandon https://orcid.org/0000-0002-6319-2228
Castillo, Cristina
Hsu, Peggy P.
Do, Brian T. https://orcid.org/0000-0003-4992-2623
Singhal, Rashi https://orcid.org/0000-0003-2685-5667
Dame, Michael K. https://orcid.org/0000-0003-3760-1654
Lee, Ho-Joon https://orcid.org/0000-0003-3616-5387
Spence, Jason R.
Lakhal-Littleton, Samira
Vander Heiden, Matthew G. https://orcid.org/0000-0002-6702-4192
Lyssiotis, Costas A. https://orcid.org/0000-0001-9309-6141
Xue, Xiang https://orcid.org/0000-0003-4704-1814
Shah, Yatrik M. https://orcid.org/0000-0002-2487-4816
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK116555, R01DK095201)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA148828, F31CA24745701, R01CA148828, R01CA245546)
- License Information
-
More Information
Article History
Received: 29 June 2020
Accepted: 11 May 2021
First Online: 21 June 2021
Competing interests
: P.P.H. is a consultant for Auron Therapeutics. C.A.L. is an inventor on patents pertaining to Kras-regulated metabolic pathways, redox control pathways in pancreatic cancer and targeting GOT1 as a therapeutic approach (US patent nos: 2012112933-A1, 2015126580-A1 and 20190136238). All other authors declare no competing interests.
